A Study of Two Doses of Intravenous NATRECOR hBNP (Nesiritide) in Patients With Worsening Congestive Heart Failure Who Have Difficulty Breathing at Rest
Phase 3
Completed
- Conditions
- Heart Failure, CongestiveHeart Decompensation
- Interventions
- First Posted Date
- 2006-02-08
- Last Posted Date
- 2011-06-10
- Lead Sponsor
- Scios, Inc.
- Target Recruit Count
- 127
- Registration Number
- NCT00288730
A Study to Develop Additional Safety and Clinical Experience With NATRECOR hBNP (Nesiritide) in the Treatment of Patients With Worsening Congestive Heart Failure Who Require Inpatient Intravenous Therapy With Medications That Influence the Tone and Caliber of Blood Vessels
Phase 3
Completed
- Conditions
- Heart Failure, CongestiveHeart Decompensation
- First Posted Date
- 2006-01-02
- Last Posted Date
- 2011-03-04
- Lead Sponsor
- Scios, Inc.
- Target Recruit Count
- 305
- Registration Number
- NCT00271557
FUSION I Assesses Safety and Tolerability of Two Doses of NATRECOR (Nesiritide) Administered to Patients With Worsening Congestive (Decompensated) Heart Failure Who Are Concurrently Receiving Their Usual Cardiac Medications and Are at High Risk for Hospitalization.
Phase 3
Completed
- Conditions
- Heart Failure, Congestive
- Interventions
- Drug: usual long term cardiac medications
- First Posted Date
- 2005-12-26
- Last Posted Date
- 2011-07-26
- Lead Sponsor
- Scios, Inc.
- Target Recruit Count
- 214
- Registration Number
- NCT00270361
A Study of Short-Term Outcomes and Economic Impact For Patients With Worsening Congestive Heart Failure When Natrecor (Nesiritide) is Added to Standard-Care Therapy, Compared to Administration of Placebo With Standard-Care Therapy
Phase 3
Completed
- Conditions
- CardiomyopathiesHeart Failure, CongestiveDyspnea, Paroxysma
- Interventions
- Drug: Natrecor (nesiritide)
- First Posted Date
- 2005-12-26
- Last Posted Date
- 2012-12-13
- Lead Sponsor
- Scios, Inc.
- Target Recruit Count
- 250
- Registration Number
- NCT00270387
A Study Comparing Blood Flow and Clinical and Safety Effects of the Addition of Natrecor (Nesiritide), Placebo or Intravenous Nitroglycerin to Standard Care for the Treatment of Worsening Congestive Heart Failure.
Phase 3
Completed
- Conditions
- Symptomatic Decompensated Congestive Heart FailureCongestive Heart Failure in Acute Coronary Syndrome
- Interventions
- First Posted Date
- 2005-12-26
- Last Posted Date
- 2011-06-10
- Lead Sponsor
- Scios, Inc.
- Target Recruit Count
- 498
- Registration Number
- NCT00270374
A Safety Study Comparing Natrecor (Nesiritide) Versus Dobutamine Therapy for Worsening Congestive Heart Failure
- First Posted Date
- 2005-12-26
- Last Posted Date
- 2011-06-10
- Lead Sponsor
- Scios, Inc.
- Target Recruit Count
- 255
- Registration Number
- NCT00270400
SCIO-469: Open-Label Study for Patients With Myelodysplastic Syndromes.
Phase 2
Completed
- Conditions
- Bone Marrow DiseasesMyelodysplastic SyndromesHematologic DiseasesBone Marrow Neoplasms
- Interventions
- First Posted Date
- 2005-06-13
- Last Posted Date
- 2013-11-07
- Lead Sponsor
- Scios, Inc.
- Target Recruit Count
- 62
- Registration Number
- NCT00113893
Extension Study of the Efficacy and Safety of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma
- First Posted Date
- 2004-11-08
- Last Posted Date
- 2010-10-22
- Lead Sponsor
- Scios, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT00095680
A Study of the Safety and Efficacy of Follow-up Serial Infusions of Natrecor(Nesiritide) for the Management of Patients With Heart Failure
Phase 2
Completed
- Conditions
- Heart Failure, Congestive
- First Posted Date
- 2004-10-01
- Last Posted Date
- 2011-05-20
- Lead Sponsor
- Scios, Inc.
- Target Recruit Count
- 920
- Registration Number
- NCT00091520
SPRiNG: SCIO-469 Patients With Rheumatoid Arthritis Not Receiving Methotrexate
- First Posted Date
- 2004-08-20
- Last Posted Date
- 2010-10-18
- Lead Sponsor
- Scios, Inc.
- Target Recruit Count
- 302
- Registration Number
- NCT00089921
© Copyright 2025. All Rights Reserved by MedPath